Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma

Journal of Vascular and Interventional Radiology

Volumn 24, Issue 3, 2013, Pages 307-315

  Prajapati, Hasmukh J ^a   Dhanasekaran, Renumathy ^a   El Rayes, Bassel F ^a   Kauh, John S ^a   Maithel, Shishir K ^a   Chen, Zhengjia ^a   Kim, Hyun S ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

adverse event; AE; AFP; alpha fetoprotein; Barcelona Clinic Liver Cancer; BCLC; DEB; drug eluting bead; Eastern Cooperative Oncology Group; ECOG; HCC; hepatocellular carcinoma; performance status; portal vein thrombosis; PS; PVT; SHARP; Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol; TACE; transarterial chemoembolization

Indexed keywords

DOXORUBICIN; SORAFENIB;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; ARTICLE; BRADYCARDIA; CANCER ADJUVANT THERAPY; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; DRUG EFFICACY; DRUG ELUTING BEAD; DRUG SAFETY; FEMALE; FEMORAL ARTERY PSEUDOANEURYSM; FEVER; FOLLOW UP; GASTROINTESTINAL DISEASE; GROIN PAIN; HUMAN; LIVER CELL CARCINOMA; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; PRIORITY JOURNAL; SUSTAINED RELEASE PREPARATION; THORAX PAIN;

AGED; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CHI-SQUARE DISTRIBUTION; DOXORUBICIN; ETHIODIZED OIL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84874775503     PISSN: 10510443     EISSN: 15357732     Source Type: Journal    
DOI: 10.1016/j.jvir.2012.11.026     Document Type: Article

References (23)

1. J.M. Llovet, C. Bru, and J. Bruix Prognosis of hepatocellular carcinoma: the BCLC staging classification Semin Liver Dis 19 1999 329 338
2. J.M. Llovet, A. Burroughs, and J. Bruix Hepatocellular carcinoma Lancet 362 2003 1907 1917
3. J. Bruix, and M. Sherman Management of hepatocellular carcinoma Hepatology 42 2005 1208 1236
4. J. Bruix, M. Sherman, and J.M. Llovet Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver J Hepatol 35 2001 421 430
5. A.-L. Cheng, Y.-K. Kang, and Z. Chen Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 10 2009 25 34
6. J.M. Llovet, S. Ricci, and V. Mazzaferro Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
7. J.M. Llovet, and J. Bruix Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival Hepatology 37 2003 429 442
8. P.M. Lopez, A. Villanueva, and J.M. Llovet Systematic review: evidence-based management of hepatocellular carcinoma - an updated analysis of randomized controlled trials Aliment Pharmacol Ther 23 2006 1535 1547
9. J. Lammer, K. Malagari, and T. Vogl Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study Cardiovasc Intervent Radiol 33 2010 41 52
10. K. Malagari, K. Chatzimichael, and E. Alexopoulou Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients Cardiovasc Intervent Radiol 31 2008 269 280
11. R. Dhanasekaran, D.A. Kooby, C.A. Staley, J.S. Kauh, V. Khanna, and H.S. Kim Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC) J Surg Oncol 101 2010 476 480
12. M. Pinter, F. Hucke, and I. Graziadei Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib Radiology 263 2012 590 599
13. H.J. Prajapati, S. Rafi, B.F. El-Rayes, J.S. Kauh, D.A. Kooby, and H.S. Kim Safety and feasibility of same-day discharge of patients with unresectable hepatocellular carcinoma treated with doxorubicin drug-eluting bead transcatheter chemoembolization J Vasc Interv Radiol 23 2012 1286 1293
14. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 4. United States Department of Health and Human Services, 2009. Available at: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14- QuickReference-5x7.pdf. Accessed February 22, 2012.
15. D.B. Brown, J.E. Gould, and D.A. Gervais Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria J Vasc Interv Radiol 20 2009 425 434
16. R.J. Lewandowski, M.F. Mulcahy, and L.M. Kulik Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort Radiology 255 2010 955 965
17. R. Salem, R.J. Lewandowski, and M.F. Mulcahy Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes Gastroenterology 138 2010 52 64
18. R. Dhanasekaran, D.A. Kooby, C.A. Staley, J.S. Kauh, V. Khanna, and H.S. Kim Prognostic factors for survival in patients with unresectable hepatocellular carcinoma undergoing chemoembolization with doxorubicin drug-eluting beads: a preliminary study HPB (Oxford) 12 2010 174 180
19. H.T. Hu, J.H. Kim, and L.S. Lee Chemoembolization for hepatocellular carcinoma: multivariate analysis of predicting factors for tumor response and survival in a 362-patient cohort J Vasc Interv Radiol 22 2011 917 923
20. C. Lance, G. McLennan, and N. Obuchowski Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma J Vasc Interv Radiol 22 2011 1697 1705
21. S. Miyayama, M. Yamashiro, and M. Okuda Chemoembolization for the treatment of large hepatocellular carcinoma J Vasc Interv Radiol 21 2010 1226 1234
22. R. Sacco, I. Bargellini, and M. Bertini Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma J Vasc Interv Radiol 22 2011 1545 1552
23. D.B. Brown, B. Nikolic, and A.M. Covey Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy J Vasc Interv Radiol 23 2012 287 294